&Partners’s BlackRock Capital Allocation Term Trust BCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$677K Buy
47,914
+1,762
+4% +$26K ﹤0.01% 1526
2025
Q4
$654K Buy
46,152
+30,033
+186% +$435K ﹤0.01% 1471
2025
Q3
$238K Buy
16,119
+233
+1% +$3.49K ﹤0.01% 1872
2025
Q2
$241K Sell
15,886
-344
-2% -$5.02K ﹤0.01% 1743
2025
Q1
$233K Buy
16,230
+808
+5% +$12.3K ﹤0.01% 1546
2024
Q4
$238K Buy
15,422
+4,300
+39% +$69.1K ﹤0.01% 1458
2024
Q3
$183K Buy
+11,122
New +$182K ﹤0.01% 1317

Other funds holding BCAT

&Partners's BCAT Position: Q1 2026 in Review

&Partners increased its BlackRock Capital Allocation Term Trust (BCAT) stake by 3.8% in Q1 2026, buying an estimated $26K and bringing the position to 47,914 shares worth $677K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

&Partners first reported a position in BCAT in Q3 2024 and has held it in 7 quarters since. 100 funds tracked by Wall St. Rank hold BCAT as of Q1 2026.

  • &Partners held 47,914 shares of BlackRock Capital Allocation Term Trust worth $677K as of Q1 2026.
  • &Partners bought 1,762 BlackRock Capital Allocation Term Trust shares in Q1 2026, an estimated $26K.
  • BlackRock Capital Allocation Term Trust made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1526 holding.
  • &Partners first reported a position in BlackRock Capital Allocation Term Trust in Q3 2024 and has held it in 7 quarters since.
  • 100 funds tracked by Wall St. Rank held BlackRock Capital Allocation Term Trust as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.